Elyse Stock - 14 Dec 2021 Form 4 Insider Report for Biohaven Pharmaceutical Holding Co Ltd.

Role
Chief Medical Officer
Signature
/s/ Jim Engelhart, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
14 Dec 2021
Net transactions value
-$2,625,376
Form type
4
Filing time
16 Dec 2021, 20:04:36 UTC
Previous filing
26 Nov 2021
Next filing
07 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BHVN Common Shares Options Exercise $69,896 +3,362 +45% $20.79* 10,829 14 Dec 2021 Direct F1
transaction BHVN Common Shares Options Exercise $38,703 +3,577 +33% $10.82* 14,406 14 Dec 2021 Direct F1
transaction BHVN Common Shares Sale $728,762 -6,939 -48% $105.02* 7,467 14 Dec 2021 Direct F1, F2
transaction BHVN Common Shares Options Exercise $145,447 +6,996 +94% $20.79* 14,463 15 Dec 2021 Direct F1
transaction BHVN Common Shares Options Exercise $161,467 +14,923 +103% $10.82* 29,386 15 Dec 2021 Direct F1
transaction BHVN Common Shares Sale $2,143,426 -20,330 -69% $105.43* 9,056 15 Dec 2021 Direct F1, F3
transaction BHVN Common Shares Sale $168,701 -1,589 -18% $106.17* 7,467 15 Dec 2021 Direct F1, F4
holding BHVN Common Shares 2,187 14 Dec 2021 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BHVN Employee Stock Option (Right to Buy) Options Exercise $0 -3,362 -15% $0.000000 18,534 14 Dec 2021 Common Shares 3,362 $20.79 Direct F1, F5
transaction BHVN Employee Stock Option (Right to Buy) Options Exercise $0 -3,577 -19% $0.000000 14,923 14 Dec 2021 Common Shares 3,577 $10.82 Direct F1, F6
transaction BHVN Employee Stock Option (Right to Buy) Options Exercise $0 -6,996 -38% $0.000000 11,538 15 Dec 2021 Common Shares 6,996 $20.79 Direct F1, F5
transaction BHVN Employee Stock Option (Right to Buy) Options Exercise $0 -14,923 -100% $0.000000* 0 15 Dec 2021 Common Shares 14,923 $10.82 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.00 - $105.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.00 - $105.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.00 - $106.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F5 The shares underlying this option vested as to 25% of the shares on December 7, 2018, the grant date, and the remainder vested in 3 equal installments on the first, second and third anniversaries of the grant date.
F6 The shares underlying this option vested as to 25% of the shares on April 6, 2017, the grant date, and the remainder vested in 3 equal installments on the first, second and third anniversaries of the grant date